1. Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, et al. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation.2017;135:e146-e603.
2. Kjeldsen SE, von Lueder TG, Smiseth OA, Wachtell K, Mistry N, Westheim AS, et al. Medical therapies for heart failure with preserved ejection fraction. Hypertension. 2020;75(1):23-32.
3. Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J.2011;32(6):670-679.
4. Shah AM, Pfeffer MA. The many faces of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2012;9(10):555-556.
5. Kao DP, Lewsey JD, Anand IS, Massie BM, Zile MR, Carson PE, et al. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. Eur J Heart Fail. 2015;17(9):925-935.
6. Hedman AK, Hag C, Sharma A, Brosnan MJ, Buckbinder L, Gan LM, et al. Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning. Heart. 2020;106(5):342-349.
7. Shah SJ, Katz DH, Selvaraj S, Burke MA, Yancy CW, Gheorghiade M, et al. Phenomapping for novel classification of heart failure with preserved ejection fraction. Circulation. 2015;131(3):269-279.
8. Cohen JB, Schrauben SJ, Zhao L, Basso MD, Cvijic ME, Li Z, et al. Clinical phenogroups in heart failure with preserved ejection fraction: detailed phenotypes, prognosis, and response to spironolactone. JACC Heart Fail. 2020;8(3):172-184.
9. Segar MW, Patel KV, Ayers C, Basit M, Wilson Tang WH, Willett D, et al. Phenomapping of patients with heart failure with preserved ejection fraction using machine learning-based unsupervised cluster analysis. Eur J Heart Fail. 2020;22(1):148-158.
10. Gu J, Pan JA, Lin H, Zhang JF, Wang CQ, et al. Characteristics, prognosis and treatment response in distinct phenogroups of heart failure with preserved ejection fraction. Int J Cardiol. 2021;323:148-154.
11. McMurray JJV, Jackson AM, Lam CSP, Redfield MM, Anand IS, Ge J, et al. Effects of sacubitril-valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction: Insights From PARAGON-HF. Circulation. 2020; 141(5):338-351
12. Gu J, Yin ZF, Zhang HL, Fan YQ, Zhang JF, Wang CQ, et al. Characteristics and outcomes of transitions among heart failure categories: a prospective observational cohort study. ESC Heart Fail. 2020;7(2):616-625.
13. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018; 39(2):119-177.
14. Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(3): 267-315.
15. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD, et al. Fourth universal definition of myocardial infarction. J Am Coll Cardiol. 2018;72(18):2231-2264.
16. Kamon D, Sugawara Y, Soeda T, Okamura A, Nakada Y, Hashimoto Y, et al. Predominant subtype of heart failure after acute myocardial infarction is heart failure with non-reduced ejection fraction. ESC Heart Fail. 2020;8(1):317-325.
17. Matsushita K, Harada K, Miyazaki T, Miyamoto T, Kohsaka S, Iida K, et al. Different prognostic associations of beta-blockers and diuretics in heart failure with preserved ejection fraction with versus without high blood pressure. J Hypertens. 2019;37(3):643-649.
18. Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381(17):1609-1620.
19. Wintrich J, Kindermann I, Ukena C, Selejan S, Werner C, Maack C, et al. Therapeutic approaches in heart failure with preserved ejection fraction: past, present, and future. Clin Res Cardiol. 2020;109(9):1079-1098.
20. Cunningham JW, Vaduganathan M, Claggett BL, Zile MR, Anand IS, Packer M, et al. Effects of sacubitril/valsartan on N-terminal pro-B-type natriuretic peptide in heart failure with preserved ejection fraction. JACC Heart Fail. 2020;8(5):372-381.
21. Sakata Y, Tsuji K, Nochioka K, Shimokawa H. Transition of left ventricular ejection fraction in heart Failure. Adv Exp Med Biol. 2018;1067:5-15.
22. Park CS, Park JJ, Mebazaa A, Oh IY, Park HA, Cho HJ, Lee HY, et al. Characteristics, outcomes, and treatment of heart failure with improved ejection fraction. J Am Heart Assoc. 2019;8:e011077.
23. Park JJ, Park CS, Mebazaa A, Oh IY, Park HA, Cho HJ, et al. Characteristics and outcomes of HFpEF with declining ejection fraction. Clin Res Cardiol. 2020;109(2):225-234.